Caplin Point Laboratories (NSE:CAPLIPOINT) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CAPLIPOINT Caplin Point Laboratories Ltd NSE:CAPLIPOINT
91 GF Score
Price ₹2,486.60
GF Value ₹2,093.91
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caplin Point Laboratories Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Caplin Point Laboratories is: Low Risk: Strong fundamentals, worth long-term holding.

Caplin Point Laboratories  (NSE:CAPLIPOINT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Caplin Point Laboratories Risk Assessment Related Terms

NSE:CAPLIPOINT vs ZTS, UTHR: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caplin Point Laboratories Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Risk Assessment falls into.


NSE:CAPLIPOINT
91GF Score
Caplin Point Laboratories Ltd NSE:CAPLIPOINT
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?

Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued. The current stock price of ₹2,486.60 is trading 18.8% above its estimated GF Value™ of ₹2,093.91. GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:CAPLIPOINT:

  • Risk Assessment:
  • GF Value™: ₹2,093.91 vs. price of ₹2,486.60 (18.8% above fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caplin Point Laboratories Business Description

Other Exchanges 524742:India
Address Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
91GF Score

Get the complete analysis for NSE:CAPLIPOINT

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,486.60
Price
₹2,093.91
GF Value